Montalvo-Villalba MC, Barroso-González P, Lopez-Hernández D, Bello-Corredor M, Marrero-Sánchez B, Rodriguez-Lay LA

Language: Spanish
References: 16
Page: 143--151
PDF size: 280.50 Kb.

ABSTRACT

Introduction. Host genetic factors like polymorphism of cytokine genes and the integrity of axis interleukin 12/interferon gamma (IL-12/INF-γ) could be related with anti-HBsAg response induced after HBV vaccination.
Objectives. To determinate the influence of single nucleotide polymorphism (SNP) of IL-12 and INF-γ mRNA expression in the antibody response to recombinant vaccine against hepatitis B virus.
Material and Methods. Twelve health care workers without protective titers of anti-HBsAg were boosted with one dose of Heberbiovac HB. In addition, it was included four controls with anti-HBsAg titres ›100IU/l. SNP of IL-12A e IL-12B were identified by nucleotide sequencing. UMELISA kit was used to quantify anti-HBsAg levels at 7 and 28 days post-vaccination (DPV). IFNg mRNA expression was determined by RT-PCR real time in mononuclear cells stimulated with HBsAg obtained from vaccine.
Results. High anti-HBsAg levels (›1000IU/l) were detected in 75% (9/12) workers at 28 DPV, high frequency it was observed in the IL-12A/IL-12B allelic genotypic combinations GG/AC and GG/AA (77,7%, 7/9). Low anti- HBsAg protective levels (11-79UI/l) at 28 DPV and IFN-γ mRNA expression were detected in individuals who carried AA/AA y GG/AA (25%, 3/12) combinations. Individual with AA/AA genotype had a negative anti-HBsAg seroconversion from 33 to 11UI/l at 7 and 28 DPV.
Conclusions. SNP of IL-12 and IFN-γ expression could be mediating the quality of anti-HBsAg titers after one booster dose of Heberbiovac HB. Further studies are needed in order to identify the relevance of these and others molecular markers in immune response against HBV vaccine.

REFERENCES

1. Michel ML. Vaccination against hepatitis B: success and challenges. Medecine Sci. 2016; 32(8-9): 739-745. DOI: 10.1051/medsci/20163208022

2. Poland GA, Ovsyannikova IG, Kennedy RB, Haralambieva IH, Jacobson RM. Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. Omics J Interg Biol. 2011; 15(9): 625-636. DOI: 10.1089/omi.2011.0032

3. Grzegorzewska AE, Swiderska MK, Mostowska A, Warchol W, Jagodzinski PP. Antibodies to HBV surface antigen in relation to interferon-lambda3 in hemodialysis patients. Vaccine. 2016; 34(41): 4866-4874. DOI: 10.1016/j.vaccine.2016.08.073

4. Grzegorzewska AE, Wobszal PM, Sowinska A, Mostowska A, Jagodzinski PP. Association of the interleukin-12 polymorphic variants with the development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to vaccination or infection. Mol Biol Reports. 2013; 40(12): 6899-6911. DOI: 10.1007/s11033-013-2809-7

5. Pallás-Álvarez JR, Gómez-Holgado MS, Llorca-Díaz J, Delgado-Rodríguez M. Vacunación de la hepatitis B. Indicaciones del test serológico postvacunal y la dosis de refuerzo. Revista Española de Salud Pública. 2000; 74(5-6): 475-482. Disponible en:http://scielo.isciii.es/ pdf/resp/v74n5-6/vacuna.pdf

6. Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Imnunology, 8th ed. Philadelphia: Elsevier Saunders; 2015.

7. Kim S, Kim YK, Lee H, Cho JE, Kim HY, Uh Y., et al. Interferon gamma mRNA quantitative real-time polymerase chain reaction for the diagnosis of latent tuberculosis: a novel interferon gamma release assay. Diag Microbiol Infect Dis. 2013; 75(1): 68-72. DOI: 10.1016/j.diagmicrobio.2012.09.015

8. Anderson CL, Remschmidt C, Drobnitzky FP, Falkenhorst G, Zimmermann R, Wichmann O., et al. Hepatitis B immune status in adolescents vaccinated during infancy: A retrospective cohort study from a pediatric practice in Germany. Human vaccines & immunotherapeutics. 2016; 12(3): 779-784. DOI: 10.1080/21645515.2015.1105414

9. Brunskole Hummel I, Zitzmann A, Erl M, Wenzel JJ, Jilg W. Characteristics of immune memory 10-15 years after primary hepatitis B vaccination. Vaccine. 2016; 34(5): 636-642. DOI: 10.1016/j.vaccine.2015.12.033

10. Paradowska-Gorycka A, Sowinska A, Stypinska B, Grobelna MK, Walczyk M, Olesinska M, et al. Genetic Variants in IL-12B and IL-27 in the Polish Patients with Systemic Lupus Erythematosus. Scand J Immunol. 2016; 84(1): 49-60. DOI: 10.1111/sji.12439

11. Shen TC, Tsai CW, Chang WS, Wang S, Chao CY, Hsiao CL., et al. Association of Interleukin-12A rs568408 with Susceptibility to Asthma in Taiwan. Scient Reports. 2017; 7(1): 3199. DOI: 10.1038/s41598-017-03523-0

12. Eskandari-Nasab E, Moghadampour M, Asadi-Saghandi A, Kharazi-Nejad E, Rezaeifar A, Pourmasoumi H. Levels of interleukin-(IL)-12p40 are markedly increased in Brucellosis among patients with specific IL-12B genotypes. Scand J Immunol. 2013; 78(1): 85-91. DOI: 10.1111/sji.12054

13. Ustáriz C, Morera LM, Hernández P, Estrada M, Bencomo A, García MA, de la Guardia MA. Origin and genetic composition of the Cuban population. Revista Cubana de Hematología, Inmunología y Hemoterapia 2011; 27(3):273-282. Disponible en: http://scielo.sld. cu/scielo.php. Acceso 10 de abril de 2019.

14. Estévez ZC, Betancourt AA, González VM, Baile NF, Silva CV, et al. Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults. Biologicals 2007; 35(2):115-122. DOI: https:// doi.org/10.1016/j.biologicals.2006.06.001.

15. Ramírez-Bello J, Vargas-Alarcón G, Tovilla-Zárate C, Fragoso JM. Polimorfismos de un solo nucleótido (SNP): implicaciones funcionales de los SNP reguladores (rSNP) y de los SNP-ARN estructurales (srSNP) en enfermedades complejas. Gaceta Médica de México. 2013; 149:220- 8 Disponible en: https://www.anmm.org.mx/ GMM/2013/n2/GMM_149_2013_2_220-228. pdf

16. Tan A, Gao Y, Yao Z, Su S, Jiang Y, Xie Y., et al. Genetic variants in IL12 influence both hepatitis B virus clearance and HBV-related hepatocellular carcinoma development in a Chinese male population. Tumour Biol. 2016; 37(5): 6343-6348. DOI: 10.1007/s13277-015-4520-x